Introduction
Etanercept is a tumour necrosis factor (TNF) blocker that binds to TNF and blocks its interaction with TNF receptors. The recommended starting dose for adults with plaque psoriasis is 50 mg twice weekly (BIW) for 3 months followed by maintenance dose of 50 mg once weekly (QW). Some patients are unable to maintain response after transitioning to maintenance dose and require treatment supplementation. Topical corticosteroid therapies have been used with etanercept for psoriasis, [1] [2] [3] and addition of clobetasol propionate to etanercept has been shown to increase efficacy compared with etanercept alone. 3 Further clinical studies are needed to identify effective treatment regimens and provide information on when to initiate treatment with topical medications. REFINE, the Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg QW plus as Needed topical agent vs. Etanercept 50 mg BIW in patients with moderate-to-severe plaque psoriasis study, was designed to evaluate efficacy and safety of adding topical corticosteroid therapy when etanercept dosage is reduced from initial dose to maintenance dose.
Patients and methods

Study design
This phase 3b, multicentre, randomized, open-label study was conducted in accordance with the Declaration of Helsinki. The study protocol and consent was approved by the institutional review board at each study site. All patients provided written informed consent before initiation of study-related procedures. This study was registered under ClinicalTrials.gov identifier NCT01313221.
All patients received etanercept 50 mg BIW for the first 12 weeks of the study. Patients were then randomized (1:1) to receive etanercept 50 mg BIW for 12 weeks or etanercept 50 mg QW plus topical agent for 12 weeks. Randomization was stratified by body mass index (BMI; ≤30 kg/m 2 or >30 kg/m 2 ) and previous TNF-blocker exposure. Patients receiving topical agents were treated as needed to achieve a target static physician global assessment (sPGA) score of 0 (clear). Topical agent was selected by the investigator from hydrocortisone 2.5%, betamethasone valerate 0.1%, betamethasone dipropionate 0.05%, clobetasol 0.05%, calcitriol, or calcipotriol plus betamethasone dipropionate 0.05%. Change in topical agent was allowed.
Patients
Eligible patients had stable moderate-to-severe plaque psoriasis for ≥6 months, psoriasis-affected body surface area (BSA) ≥10%, Psoriasis Area and Severity Index (PASI) score ≥10, and qualified as a candidate for systemic therapy or phototherapy. Exclusions included guttate, erythrodermic or pustular psoriasis or significant concurrent medical conditions.
Endpoints
The 
Statistical considerations
Three hundred patients (150 per arm) were estimated to provide a 95% confidence interval (CI) for difference between treatment arms of mean percentage change in PASI with a half-width of 7.2% and to accommodate a 10% attrition rate. Efficacy analyses were conducted on all randomized patients with ≥1 postrandomization efficacy evaluation. Some efficacy analyses were also done on the full analysis set of all enrolled patients with ≥1 postbaseline efficacy evaluation. Least squares means and 95% CIs for treatment difference in percentage change in PASI and affected BSA from week 12 were calculated using repeated measures models across weeks 16, 20 and 24 with no imputation for missing data. Secondary endpoints were summarized by mean, standard deviation (SD), 95% CI, or percentage for categorical variables. Last observation carried forward imputation was used for missing data for some secondary endpoints. Multiple imputation was used for sensitivity analyses on summary statistics for primary and some secondary endpoints. 4 AEs were summarized and coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 15.1. Statistical analyses were performed using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA).
Results
Patients
Of 310 patients enrolled, 144 were randomized to etanercept, 143 to etanercept+topical, and 23 discontinued prior to week 12 and were not randomized. Forty-three (13.9%) patients discontinued because of withdrawn consent (n = 10), loss to follow-up (n = 10), AE (n = 7), non-compliance (n = 5), protocol violation (n = 2), disease progression (n = 2), requirement for alternative therapy (n = 2), administrative decision (n = 2), pregnancy (n = 2) and other reasons (n = 1) (Fig. 1) .
The population was predominantly white (87.7%); most patients were men (64.8%), and mean (SD) age was 45.3 (13.9) years (Table 1 ). Demographic and clinical characteristics were similar across treatment arms; non-randomized patients were mostly women (60.9%), were younger, appeared to have milder disease (lower mean PASI score, smaller percentage affected BSA), and were less likely to have psoriatic arthritis than randomized patients ( Table 1) .
The full analysis set comprised all patients in the two treatment arms. Of randomized patients, 140 (97.2%) receiving etanercept and 142 (99.3%) receiving etanercept+topical were included in the efficacy evaluable set (Fig. 1 ). All patients were included in the safety analysis set.
Of patients randomized to etanercept+topical, 11 (7.7%) decided not to use a topical agent. One patient in the etanercept monotherapy arm used a topical agent. Of patients who used topical therapies, 65 (48.9%) used calcipotriol plus betamethasone dipropionate 0.05%, 33 (24.8%) used betamethasone valerate 0.1%, 23 (17.3%) used betamethasone dipropionate 0.05%, 19 (14.3%) used clobetasol 0.05%, 12 (9.0%) used hydrocortisone 2.5% and 3 (2.3%) used calcitriol. One hundred and ten (82.7%) patients used 1 topical agent, 21 (15.8%) used 2 topical agents, and 1 (0.8%) used ≥3 topical agents. Topical agents were applied for mean (SD) of 51 (26) 
Changes in PASI scores and PASI responses
The percentage change from week 12 in PASI score was similar between treatment arms at weeks 16, 20, and 24 ( 
Changes in BSA
Improvements in psoriasis-affected BSA were similar between treatment arms from week 12 to weeks 16, 20 and 24 (Table 4) . At week 24, percentage change in psoriasis-affected BSA from week 12 was 15.6% (À4.4%, 35.6%) for the etanercept arm and 10.7% (À9.3%, 30.7%) for the etanercept+topical arm.
Safety
Approximately two-thirds of all patients reported ≥1 treatment-emergent AE (Table 5 ). There were a total of 138.1 patient-years of etanercept exposure across all 310 patients with a total of 603 AEs. The event rate was highest in the Etanercept plus topicals for psoriasis non-randomized group. The most commonly reported AEs were nasopharyngitis (n = 44; 14.2%), injection site reaction (n = 33; 10.6%) and headache (n = 28; 9.0%). No fatal events occurred. The PsoRiasis study to assess effIcacy and SafeTy IN subjects taking Etanercept 50 mg once weekly and twice weekly with adjunct therapy (PRISTINE) study compared patients who initiated etanercept at 50 mg BIW for 12 weeks and then received a maintenance dose of 50 mg QW (BIW/QW group) with patients who received the 50 mg QW dose (QW/QW group) throughout the study. 2 Patients were allowed to use any topical medication after week 12. At week 24, 59.9% in the QW/QW group and 78.2% of the BIW/QW group achieved PASI 75 response. Mean percentage improvement in the QW/QW and BIW/QW groups, respectively, was 58.5% and 74.1% at week 12 and 70.7% and 81.3% at week 24. Only 23% of patients receiving BIW/QW dosing and 28% of patients receiving QW/ QW dosing elected to use topical medications through week 24. In contrast, 92% of patients in the etanercept+topical arm of our study used topical medications. This difference in rates of topical medication usage could be related to instructions provided to patients (topical medications were used as needed in PRISTINE, but were used as needed to clear in REFINE) and source of topical medications (provided by patients in PRIS-TINE and by the sponsor in REFINE).
Discussion
Patients in the adalimumab in combination with topical Treatment [Calcipotriol/Betamethasone] in subjects with moderate to severe psoriasis and insufficient response to classic systemic treatment (BELIEVE) study received adalimumab with either topical calcipotriol betamethasone or vehicle for 4 weeks and then topical therapies as needed for 12 weeks. 6 A greater proportion of patients receiving adalimumab plus topical calcipotriol betamethasone achieved PASI 75 response at weeks 2 (P < 0.001) and 4 (P = 0.02), but patients on adalimumab monotherapy showed better clinical responses after week 4 through week 16. In contrast, patients in REFINE did not initiate topical therapy until they had received etanercept for 12 weeks and patients on etanercept monotherapy did not achieve greater clinical benefit than patients using topical medications. Together, these results support the use of topical medications in combination with TNF blocker therapies in patients with psoriasis. A limitation of the study was the short duration of treatment (12 weeks of etanercept plus topical therapies), which may not accurately reflect long-term results as adherence with topical therapies may decrease with time. 7, 8 Treatment responses were similar between patients on etanercept 50 mg BIW and those on 50 mg QW who used topical medications as needed to clear. Patients who received the lower dose of 50 mg QW at week 12 and those who stayed on etanercept 50 mg BIW were both able to maintain their clinical response through week 24. Patients received ETN 50 mg BIW during the first 12 weeks, but discontinued the study before randomization to a treatment arm. AEs, adverse events; BIW, twice weekly; DC, discontinuation; ETN, etanercept; IP, investigational product; QW, once weekly.
